title: [Cytokine in phenotypic analysis of leukemia/lymphoma: suppression of gene expression of myeloperoxidase by IFN-gamma and subset of AML M1 defined by CD45RO+/RA-, CD7(-), CD34(-) and non-inducible HLA-DR antigen].
abstract: One of 8 to 12 pre-B ALL cells co-express CD13 and CD33 antigens, but such blasts do not express myeloperoxidase (MPO) even on electronmicroscopy or mRNA. MPO+ pre-B ALL is extremely rare (1/50-1/100), however a cell-line (Tahr87) was established in culture. In contrast, T-lineage blasts express CD13/33 antigens regularly in the pro-thymic stage (CD7+ 5+ 2+ 3- 4- 8- or more immature), and a limited expression of MPO is rather commonly detected particularly in recurrences. The co-expression of CD3 epsilon/MPO or CD3 epsilon/delta/MPO mRNA has been demonstrated. Thus, the regulation of MPO expression is of utmost importance in interpreting the phenotypes of leukemia/lymphoma. While testing the effects of several cytokines on MPO expression, IFN-gamma was found to suppress the gene expression of MPO in HL60 cells. This suppression was not accompanied by differentiation, termination of proliferation or reduction of cytochemical MPO+ cells, and was reversible. Among 22 cases of M1 AML blasts, 8 cases were HLA-DR(-). DR antigen was induced by the presence of a mixture of IFN-gamma, TNF-alpha and TPA in 4 cases, but not in the other 4 cases. The blasts of the latter 4 cases were always CD34(-), CD7(-) and CD45RA-/RO+, and constituted a distinct M1 subset which has not previously been reported.
authors.affiliation: Department of Laboratory Medicine, Kobe University School of Medicine.
authors.forename: E
authors.initials: E
authors.lastname: Tatsumi
authors.forename: N
authors.initials: N
authors.lastname: Yoneda
authors.forename: S
authors.initials: S
authors.lastname: Kawano
authors.forename: N
authors.initials: N
authors.lastname: Yamaguchi
mesh_terms: D015703:Antigens, CD / Q000032:analysis*; D018952:Antigens, CD34; D019011:Antigens, CD7; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis*; D015973:Gene Expression Regulation, Leukemic; D015972:Gene Expression Regulation, Neoplastic; D006684:HLA-DR Antigens / Q000378:metabolism*; D006801:Humans; D016130:Immunophenotyping; D007371:Interferon-gamma / Q000494:pharmacology*; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000276:immunology; D017493:Leukocyte Common Antigens / Q000032:analysis*; D008223:Lymphoma / Q000235:genetics*; D009195:Peroxidase / Q000235:genetics*; D010641:Phenotype
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34; D019011:Antigens, CD7; D000945:Antigens, Differentiation, T-Lymphocyte; D006684:HLA-DR Antigens; D007371:Interferon-gamma; D009195:Peroxidase; D017493:Leukocyte Common Antigens